Renishaw Diagnostics Ltd, developers of the RenDx™ Multiplex Assay System for infectious disease research and diagnosis, today announced that it has been certified to ISO 13485:2003 for the following scope: design, development, product manufacture and management of subcontracted manufacture of molecular diagnostic systems for infectious diseases.
Renishaw Diagnostics Ltd, a world leading provider of trace level detection technologies based on the exploitation of surface enhanced Raman scattering (SERS) and surface enhanced resonance Raman scattering (SERRS) for infectious disease research and molecular diagnostics applications, today announced that it has established a contract reagent manufacturing agreement with Gen-Probe’s Cardiff facility.
Renishaw Diagnostics Ltd, today announced that it has concluded an exclusive licence agreement to a patent on nucleic acid sequence identification (SERRS beacons) from The University of Strathclyde.
Renishaw Diagnostics Ltd (formerly D3 Technologies), a world leading provider of trace level detection technologies based on the exploitation of surface enhanced Raman scattering (SERS) and surface enhanced resonance Raman scattering (SERRS), for research and molecular diagnostics applications, today announced details of a talk to be presented at PittCon 2011 in Atlanta, Georgia later this month.
Renishaw Diagnostics Ltd, a world leading provider of trace level detection technologies based on the exploitation of surface enhanced Raman scattering (SERS) and surface enhanced resonance Raman scattering (SERRS), for research and molecular diagnostics applications, today announced the launch of its first research use only (RUO) multiplex assay system which allows precious research samples to be ‘screened’ for 10 or more ‘targets’, from a single sample.
Renishaw Diagnostics Ltd, a world leading provider of trace level detection technologies based on the exploitation of surface enhanced resonance Raman scattering (SERRS), for life science research and molecular diagnostics applications, today announced its intention to create another 7 new jobs immediately: almost a 30% increase on its current workforce.
Renishaw is pleased to announce it has acquired a 75% interest in D3 Technologies Limited, "D3" (now Renishaw Diagnostics Ltd), a company set up in collaboration with the University of Strathclyde and others to exploit certain patents related to Surface Enhanced Raman Spectroscopy ("SERS") and to develop SERS for molecular diagnostics and trace detection.
D3 Technologies Limited (now Renishaw Diagnostics Ltd.), a leader in Surface Enhanced Raman Spectroscopy (SERS), and a subsidiary of world-leading metrology and spectroscopy company Renishaw plc, was honoured with a spin-out recognition award at the recent University of Strathclyde Enterprise Awards. The award recognised D3 for its work on trace detection used in drug development, forensic science and medical diagnostics.
Renishaw Diagnostics (previously D3 Technologies Ltd) and the research team in the Department of Medical Microbiology, School of Medicine Cardiff University, in association with the National Public Health Service for Wales, have signed an agreement to develop an advanced multiplex pan-fungal diagnostic assay.
Renishaw Diagnostics (previously D3 Technologies Ltd) is developing a new cleaning verification procedure which cuts swab and rinse analysis time from days to hours, significantly reducing production downtime.
Renishaw Diagnostics Ltd, developers of the RenDx™ Multiplex Assay System for infectious disease research and diagnosis, today announced that it has been certified to ISO 13485:2003 for the following scope: design, development, product manufacture and management of subcontracted manufacture of molecular diagnostic systems for infectious diseases.
Renishaw Diagnostics Ltd, a world leading provider of trace level detection technologies based on the exploitation of surface enhanced Raman scattering (SERS) and surface enhanced resonance Raman scattering (SERRS) for infectious disease research and molecular diagnostics applications, today announced that it has established a contract reagent manufacturing agreement with Gen-Probe’s Cardiff facility.
Renishaw Diagnostics Ltd (formerly D3 Technologies), a world leading provider of trace level detection technologies based on the exploitation of surface enhanced Raman scattering (SERS) and surface enhanced resonance Raman scattering (SERRS), for research and molecular diagnostics applications, today announced details of a talk to be presented at PittCon 2011 in Atlanta, Georgia later this month.
Renishaw Diagnostics Ltd, a world leading provider of trace level detection technologies based on the exploitation of surface enhanced Raman scattering (SERS) and surface enhanced resonance Raman scattering (SERRS), for research and molecular diagnostics applications, today announced the launch of its first research use only (RUO) multiplex assay system which allows precious research samples to be ‘screened’ for 10 or more ‘targets’, from a single sample.
Renishaw Diagnostics (previously D3 Technologies Ltd) and the research team in the Department of Medical Microbiology, School of Medicine Cardiff University, in association with the National Public Health Service for Wales, have signed an agreement to develop an advanced multiplex pan-fungal diagnostic assay.
Renishaw Diagnostics (previously D3 Technologies Ltd) is developing a new cleaning verification procedure which cuts swab and rinse analysis time from days to hours, significantly reducing production downtime.